会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • IMIDAZOQUINAZOLINE DERIVATIVES
    • 咪唑啉酮衍生物
    • WO1998008848A1
    • 1998-03-05
    • PCT/JP1997003023
    • 1997-08-29
    • KYOWA HAKKO KOGYO CO., LTD.ONODA, YasuoNOMOTO, YujiOHNO, TetsujiYAMADA, KojiICHIMURA, Michio
    • KYOWA HAKKO KOGYO CO., LTD.
    • C07D487/04
    • C07D487/04
    • Imidazoquinazoline derivatives represented by general formula (I) or pharmacologically acceptable salts thereof, which have potent and selective inhibitory effects on cyclic guanosine-3',5'-monophosphate (cGMP)-specific phosphodiesterase and are useful in, for example, treating or relieving cardiovascular diseases such as thrombosis, angina pectoris, hypertension, cardiac insufficiency and arteriosclerosis, asthma, etc. and treating sexual impotence. In said formula, R represents hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted bicycloalkyl, optionally substituted tricycloalkyl, etc.; R represents hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted bicyclaolkyl, optionally substituted tricycloalkyl, optionally substituted lower alkenyl, optionally substituted aralkyl, etc.; R represents hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted bicycloalkyl, optionally substituted tricycloalkyl, optionally substituted lower alkenyl, optionally substituted aralkyl, etc., or R and R may form together with N an optionally substituted heterocyclic group; and X represents O or S.
    • 对通式(I)表示的咪唑并喹唑啉衍生物或其药理学上可接受的盐,对环鸟嘌呤-3',5'-单磷酸(cGMP)特异性磷酸二酯酶具有有效和选择性的抑制作用,可用于例如治疗或缓解 心血管疾病如血栓形成,心绞痛,高血压,心功能不全和动脉硬化,哮喘等,并治疗性阳。。 在所述式中,R 1表示氢,任选取代的低级烷基,任选取代的环烷基,任选取代的双环烷基,任选取代的三环烷基等; R 2表示氢,任选取代的低级烷基,任选取代的环烷基,任选取代的双环烷基,任选取代的三环烷基,任选取代的低级烯基,任选取代的芳烷基等; R 3表示氢,任选取代的低级烷基,任选取代的环烷基,任选取代的双环烷基,任选取代的三环烷基,任选取代的低级链烯基,任选取代的芳烷基等,或R 2和R 3可与 N为任选取代的杂环基; X表示O或S.
    • 4. 发明申请
    • ENDOTHELIN-ANTAGONIZING PEPTIDE
    • 内皮素 - 拮抗肽
    • WO1995000546A1
    • 1995-01-05
    • PCT/JP1994001011
    • 1994-06-23
    • KYOWA HAKKO KOGYO CO., LTD.SHIBATA, KenjiSUZAWA, ToshiyukiYAMASAKI, MotooTANAKA, TakeoTSUKUDA, EijiYAMADA, KojiOHNO, Tetsuji
    • KYOWA HAKKO KOGYO CO., LTD.
    • C07K07/08
    • C07K7/06A61K38/00C07K14/57536
    • An endothelin-antagonizing peptide compound represented by general formula (I) and a pharmacologically acceptable salt thereof: R -R -R -R -R -R -R -R -R -R -R -R -Phe-R -R -R -R -R -Ile-R -Z wherein R is X -Gly, X (a), X -SCH2CO or hydrogen; R is Asn, Asp, Phe, Tyr, Ser or a single bond; R is Trp, Ile, Pro, Ala or a single bond; R is His, Lys, Gly, Trp, Ala or a single bond; R is Gly, Thr, Trp, Val or a single bond; R is Gly, Thr, Asn, Tyr, Asp or a single bond; R is Ala, Ser, Asn, Asp, Tyr, Phe or a single bond; R is Pro, Ala, Arg or a single bond; R is (b), (c) or a single bond; R is Trp or Ala; R is Val, Pro or a single bond; R is Tyr or a single bond; R is Ala, MeAla, Ser or Cys; R is His or Trp; R is Leu or Nva; R is Asp, Thr, Asn, Ser, Gly or Glu; R is Ile, Leu, Cha, Abu, Thi, Met, Tyr, MeLeu, MeIle, Phg or Nle; R is Trp, Phe or Tyr; and Z is hydroxy, lower alkoxy or amino.
    • 由通式(I)表示的内皮素拮抗肽化合物及其药理学上可接受的盐:R 1 -R 2 -R 3 -R 4 -R 5 -R 6 - [R <7> -R <8> -R <9> -R <10> -R <11> -R <12> -Phe-R <14> -R <15> -R <16> -R <17 其中R 1为X 1 -Gly,X 3(a),X 2 -SCH 2 CO或氢; R 2是Asn,Asp,Phe,Tyr,Ser或单键; R 3是Trp,Ile,Pro,Ala或单键; R 4是His,Lys,Gly,Trp,Ala或单键; R 5是Gly,Thr,Trp,Val或单键; R 6是Gly,Thr,Asn,Tyr,Asp或单键; R 7是Ala,Ser,Asn,Asp,Tyr,Phe或单键; Pro,Ala,Arg或单键; R 9为(b),(c)或单键; R 10是Trp或Ala; R 11是Val,Pro或单键; R 12是Tyr或单键; R 14是Ala,MeAla,Ser或Cys; R 15是His或Trp; R 16是Leu或Nva; R 17是Asp,Thr,Asn,Ser,Gly或Glu; R 18是Ile,Leu,Cha,Abu,Thi,Met,Tyr,MeLeu,MeIle,Phg或Nle; R 20是Trp,Phe或Tyr; Z为羟基,低级烷氧基或氨基。
    • 6. 发明申请
    • INFORMATION PROCESSING METHOD AND PROGRAM
    • 信息处理方法与程序
    • WO2008152954A1
    • 2008-12-18
    • PCT/JP2008/060250
    • 2008-05-28
    • CANON KABUSHIKI KAISHAYAMADA, Koji
    • YAMADA, Koji
    • G06F9/445
    • G06F21/6218G06F8/61G06F2221/2141
    • Commands such as installation operation and launch program commands need to be executed after appropriately switching between an administrator account and another account, for each command, when an installer constituting a program for readily performing installation operations collectively for a plurality of pieces of software or the like is launched. When an installer is launched in the present invention, process-to-process communication is secured between the processes of an administrator account and a user account, and an account to execute a command included in the installer is determined in the process of the administrator account. If the determination result indicates that the account to execute the command is the user account, the command is executed in the process of the user account rather than in the process of the administrator account.
    • 在安装操作和启动程序命令之间的命令需要在管理员帐户与另一个帐户之间适当地切换时对于每个命令执行,当构成用于容易地对多个软件等进行安装操作的程序的安装程序时 被推出。 当在本发明中启动安装程序时,在管理员帐户和用户帐户的处理之间确保处理到进程的通信,并且在管理员帐户的过程中确定执行安装程序中包括的命令的帐户 。 如果确定结果指示执行该命令的帐户是用户帐户,则该命令在用户帐户的过程中执行,而不是在管理员帐户的过程中执行。
    • 7. 发明申请
    • ACRIDONE COMPOUNDS
    • ACRIDONE化合物
    • WO1997012872A1
    • 1997-04-10
    • PCT/JP1996002880
    • 1996-10-03
    • EISAI CO., LTD.MIYAMOTO, MitsuakiYOSHIUCHI, TatsuyaSATO, KeizoKAINO, MakotoTAKASHIMA, YoshihiroMORIYA, KatsuhiroSAKUMA, YoshinoriYAMADA, KojiHARADA, kOkichiNISHIZAWA, YukioKOBAYASHI, SeiichiOKITA, MakotoKATAYAMA, Koichi
    • EISAI CO., LTD.
    • C07D219/14
    • C07D219/14
    • Novel acridone compounds represented by general formula (I) or pharmacologically acceptable salts thereof efficacious in the prevention and treatment of diseases in which chemical transmitters (histamine, leukotriene, etc.) participate, typified by asthma, allergic rhinitis, atopic dermatitis, urticaria, hay fever, digestive tract allergy, food allergy, etc., wherein R , R , R , R , R and R are the same or different and each represents hydrogen, hydroxy, halogeno, lower alkyl, cycloalkyl, lower alkoxy, etc.; Y represents -(CH2)t-(B)m-(CH2)-Z [wherein m is 0 or 1; t and n represent each an integer of from 0 to 6; B represents lower alkylene, optionally substituted arylene, etc.; and Z represents cyano, optionally protected carboxy, acyl or -NR R (wherein R and R are the same or different and each represents hydrogen, lower alkyl, lower alkoxy, hydroxyalkyl, etc.)]; and D represents oxygen or sulfur.
    • 由通式(I)表示的新型吖啶酮化合物或其药学上可接受的盐在预防和治疗化学发射器(组胺,白三烯等)参与的疾病中有效,以哮喘,过敏性鼻炎,特应性皮炎,荨麻疹,干草为代表 发热,消化道过敏,食物过敏等,其中R 1,R 2,R 3,R 4,R 5和R 6相同或不同,表示 氢,羟基,卤代,低级烷基,环烷基,低级烷氧基等; Y表示 - (CH 2)t - (B)m - (CH 2)-Z [其中m为0或1; t和n表示0〜6的整数。 B表示低级亚烷基,任选取代的亚芳基等; 和Z表示氰基,任意保护的羧基,酰基或-NR 7 R 8(其中R 7和R 8相同或不同,各自代表氢,低级烷基,低级烷氧基,羟基烷基等 。)]; D表示氧或硫。
    • 9. 发明申请
    • INFORMATION PROCESSING METHOD AND PROGRAM
    • 信息处理方法与程序
    • WO2008152954A4
    • 2009-04-23
    • PCT/JP2008060250
    • 2008-05-28
    • CANON KKYAMADA KOJI
    • YAMADA KOJI
    • G06F9/445
    • G06F21/6218G06F8/61G06F2221/2141
    • Commands such as installation operation and launch program commands need to be executed after appropriately switching between an administrator account and another account, for each command, when an installer constituting a program for readily performing installation operations collectively for a plurality of pieces of software or the like is launched. When an installer is launched in the present invention, process-to-process communication is secured between the processes of an administrator account and a user account, and an account to execute a command included in the installer is determined in the process of the administrator account. If the determination result indicates that the account to execute the command is the user account, the command is executed in the process of the user account rather than in the process of the administrator account.
    • 在安装操作和启动程序命令之间的命令需要在管理员帐户与另一个帐户之间适当地切换时对于每个命令执行,当构成用于容易地对多个软件等进行安装操作的程序的安装程序时 被推出。 当在本发明中启动安装程序时,在管理员帐户和用户帐户的处理之间确保处理到进程的通信,并且在管理员帐户的过程中确定执行安装程序中包括的命令的帐户 。 如果确定结果指示执行该命令的帐户是用户帐户,则该命令在用户帐户的过程中执行,而不是在管理员帐户的过程中执行。